Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akzo Nobel and Pfizer have achieved progress in their research project for the development of asenapine, a novel drug for the treatment of psychotic and mood disorders. The program is expected to be finalized by the end of 2006 with an application to market the drug anticipated in 2007.
Subscribe to our email newsletter
Akzo said the work conducted in partnership between its Organon unit and Pfizer has achieved such a significant developmental milestone that will result in a retroactive change in the division of full phase III development costs, with Pfizer increasing its share. The agreed future revenue sharing will remain in place.
The milestone relates to satisfactory results in the companies’ clinical trial program. The achievement of the milestone, of which no further specifics were disclosed, reconfirms the commitment of both companies to fully explore the clinical potential of the psychotherapeutic investigational drug.
Asenapine is a novel psychotherapeutic investigational drug being developed for the treatment of psychotic and mood disorders. It has a unique neuropharmacological receptor signature that distinguishes it from current antipsychotics, antidepressants and mood stabilizers. Early clinical results indicate that asenapine will restore balance to a patient’s life through superior relief of negative symptoms and strong control of positive symptoms in schizophrenia.